(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study | The FDA has put a clinical hold on a Tenaya ...

As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

Opus Genetics is launching a pivotal study for a gene therapy targeting a rare eye disorder that can cause blindness.

Under the subject "The Evolving Field of Cell and Gene Therapy", Cellex Cell Professionals GmbH hosted an international symposium on November 6, 2025, in Frankfurt/Main. More than 100 participants ...